Practice 5 structured short- and long-answer medical questions on Weekly Year 2: Microbiology Exam - May 29, 2026 (Sections B & C). Review model answers for...
Answer: Gram-positive bacteria possess a thick peptidoglycan layer that constitutes the majority of their cell wall. This thick layer is external to the cytoplasmic membrane and stains purple with the Gram stain. Gram-negative bacteria, on the other hand, have a much thinner peptidoglycan layer located in the periplasmic space between the inner cytoplasmic membrane and an outer membrane. The outer membrane of Gram-negative bacteria contains lipopolysaccharide (LPS) and porins. Penicillin inhibits the synthesis of peptidoglycan by targeting transpeptidases (also known as penicillin-binding proteins). The thick peptidoglycan layer of Gram-positive bacteria is readily accessible to penicillin, making them generally susceptible. In Gram-negative bacteria, the outer membrane acts as a barrier, hindering penicillin's access to the peptidoglycan layer. Additionally, some Gram-negative bacteria possess efflux pumps that can actively transport penicillin out of the cell, further contributing to resistance.
Answer: Viral replication involves a cyclical process: attachment to a host cell, penetration into the host cell, uncoating of the viral genome, synthesis of viral nucleic acids and proteins (using the host cell's machinery and resources), assembly of new virions, and release from the host cell. Viruses are obligate intracellular parasites because they lack the necessary cellular machinery (such as ribosomes, enzymes for metabolic processes, and ATP-generating systems) to replicate independently. They must infect a living host cell and hijack its metabolic processes to produce new viral particles.
Answer: Bacteremia is the presence of bacteria in the bloodstream. Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Septic shock is a subset of sepsis in which particularly profound circulatory, cellular, and metabolic abnormalities are associated with an even higher mortality risk. The host response involves an overactive and prolonged inflammatory cascade initiated by the pathogen. This can lead to the release of pro-inflammatory cytokines, endothelial damage, microvascular dysfunction, and ultimately, organ failure.
Answer: Antimicrobial resistance is the ability of microorganisms (like bacteria) to withstand the effects of antimicrobial drugs, rendering them ineffective. Common mechanisms for acquiring or developing resistance include: 1. **Enzymatic inactivation:** Bacteria produce enzymes that degrade or inactivate the antibiotic (e.g., beta-lactamases that break down penicillin). 2. **Alteration of antibiotic target:** Mutations in the bacterial gene encoding the target of the antibiotic can alter its structure, preventing the drug from binding effectively. 3. **Decreased permeability or increased efflux:** Bacteria can alter their cell membrane to reduce the uptake of antibiotics or increase the expression of efflux pumps that actively transport antibiotics out of the cell. 4. **Acquisition of resistance genes:** Bacteria can acquire resistance genes through horizontal gene transfer mechanisms such as conjugation, transduction, or transformation from other resistant bacteria.
Answer: (a) Pathogenesis of Urinary Tract Infections (UTIs): * **Ascending Infection:** The vast majority of UTIs are caused by bacteria ascending from the perineal area through the urethra into the bladder. *E. coli* is the most frequent cause of community-acquired and hospital-acquired UTIs due to its prevalence in the fecal flora. * **Virulence Factors of *E. coli*:** *E. coli* possesses several virulence factors that contribute to its ability to cause UTIs: * **Adherence:** P-pili (type 1 pili) allow *E. coli* to adhere to uroepithelial cells, preventing their clearance by urine flow. Fimbriae are also important for attachment. * **Motility:** Flagella contribute to bacterial motility, aiding in their ascent through the urinary tract. * **Biofilm Formation:** Some strains can form biofilms on medical devices or host tissues, providing a protected environment for growth and increasing resistance to antibiotics and host defenses. * **Toxin Production:** Hemolysin (HlyA) can damage host cells and contribute to pyelonephritis (kidney infection). * **Urease Production:** Some *E. coli* strains produce urease, which breaks down urea into ammonia. This alkalinizes the urine, which can promote stone formation and create an environment favorable for bacterial growth. * **Host Factors:** Factors that predispose to UTIs include anatomical abnormalities, obstruction (e.g., kidney stones, enlarged prostate), sexual activity, catheterization, and compromised immune systems (as seen in diabetes). * **Progression to Pyelonephritis:** If untreated or if virulence factors are high, bacteria can ascend from the bladder to the kidneys, causing pyelonephritis. This can lead to systemic symptoms and increase the risk of kidney damage. (b) Rationale for Nitrofurantoin Therapy and Challenges in Treatment: * **Rationale for Nitrofurantoin:** * **Culture and Sensitivity:** The urine culture demonstrated *E. coli* with sensitivity to nitrofurantoin and resistance to ampicillin. This is crucial as it dictates effective antibiotic choice. Prescribing an ineffective antibiotic (like ampicillin in this case) would lead to treatment failure. * **Mechanism of Action:** Nitrofurantoin is concentrated in the urine and acts via multiple mechanisms, including damaging bacterial DNA, RNA, and ribosomes. It is particularly effective against common uropathogens like *E. coli*. * **Urinary Tract Specificity:** Nitrofurantoin is primarily excreted by the kidneys and achieves high concentrations in the urine and bladder, making it an excellent choice for uncomplicated and complicated lower UTIs. Its systemic absorption is low, minimizing systemic side effects. * **Avoidance of Resistance:** Using nitrofurantoin avoids the use of ampicillin, to which the organism is resistant, thus preventing further selection for resistance. * **Potential Challenges in Patients with Diabetes and CKD:** * **Diabetes Mellitus:** * **Impaired Immune Response:** Diabetic patients often have a weakened immune system, making them more susceptible to infections and potentially hindering their ability to clear infections. * **Neuropathy:** Diabetic autonomic neuropathy can impair bladder emptying (neurogenic bladder), leading to urinary stasis, which is a significant risk factor for recurrent UTIs and ascending infections. * **Glycosuria:** Elevated blood glucose levels can lead to glycosuria (glucose in the urine), providing a nutrient source for bacterial growth. * **Increased Severity:** UTIs in diabetic patients are often more severe and may be more likely to progress to pyelonephritis and even urosepsis. * **Chronic Kidney Disease (CKD): * **Reduced Antibiotic Clearance:** Many antibiotics are renally excreted. In CKD, renal function is impaired, leading to reduced clearance of antibiotics. This can result in drug accumulation and increased risk of toxicity. * **Altered Drug Metabolism/Distribution:** CKD can affect drug metabolism and distribution, altering the pharmacokinetic profile of antibiotics. * **Choice of Antibiotics:** Certain antibiotics, such as nitrofurantoin, have limited efficacy or are contraindicated in patients with significantly reduced renal function (typically GFR < 30-60 mL/min, depending on the specific guideline and drug). While nitrofurantoin may still be considered for lower UTIs in some CKD patients with moderate impairment, its use in severe CKD or for pyelonephritis is often avoided due to poor tissue penetration and potential for toxicity. In this case, the patient's CKD stage would need to be considered to ensure nitrofurantoin is appropriate and at the correct dose. If renal function is severely compromised, alternative antibiotics that are safer in CKD would be necessary. * **Increased Risk of Complications:** Patients with CKD are at higher risk for complications from UTIs, including kidney damage and worsening renal function. In summary, the selection of nitrofurantoin is well-justified by the sensitivity results. However, careful monitoring of renal function and consideration of the patient's comorbidities are essential for effective and safe management of the UTI.